Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: For patients with recurrent serous borderline ovarian tumors (BOT) who have undergone unilateral salpingo-oophorectomy, there is a risk of reduced or even lost ovarian reserve after the second surgery; therefore, fertility preservation (FP) prior to re-operation in patients of childbearing age is challenging, and has attracted increasing attention. Here, we discuss the multidisciplinary whole-process management of a patient with recurrent serous BOT, from embryo cryopreservation (EC) before re-fertility-sparing surgery (re-FSS) to successful delivery.

Case Presentation: We describe the treatment of a 28-year-old married, nulliparous female with recurrent serous BOT who requested FP. The patient underwent right salpingo-oophorectomy in July 2020 for serous BOT. In March 2023, B-ultrasound indicated BOT recurrence, and she underwent a second operation. After a multidisciplinary discussion and information on the risks, the patient strongly requested EC. We used letrozole (LE) combined with an antagonist for ovarian stimulation; 16 eggs were obtained, 15 eggs were MII, four embryos on the 3rd day and one blastocyst was formed and cryopreserved. One month later, laparoscopic cystectomy was performed, and pathological examination revealed serous BOT. Three months after the operation, resuscitation and transplantation of one blastocyst did not result in pregnancy through the natural cycle (NC), followed by resuscitation and transfer of two embryos on day 3 through hormone replacement therapy (HRT), which resulted in a successful pregnancy and live healthy male birth. No recurrence was reported at 19 months after re-FSS.

Conclusions: This case highlights the key points of comprehensive multidisciplinary management from the discovery of BOT recurrence, multidisciplinary team (MDT) consultation, ovarian stimulation (OS), egg retrieval, EC, re-FSS, frozen embryo transfer (FET), to delivery. Re-FSS is safe and effective for patients with recurrent serous BOT and strong fertility requirements, and EC before re-FSS is feasible.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335055PMC
http://dx.doi.org/10.1186/s12884-025-07918-0DOI Listing

Publication Analysis

Top Keywords

recurrent serous
20
serous bot
20
multidisciplinary whole-process
8
whole-process management
8
management patient
8
patient recurrent
8
serous borderline
8
borderline ovarian
8
embryo cryopreservation
8
cryopreservation re-fertility-sparing
8

Similar Publications

Ovarian cancer (OC) remains one of the leading causes of gynecologic cancer-related mortality, with most patients presenting with disseminated disease, particularly within the peritoneal cavity. Standard treatment includes cytoreductive surgery, platinum-based chemotherapy, and targeted maintenance approaches depending on the patient's and tumor's genetic profile. Despite treatment advancements, approximately 25% of high-grade serous OC cases relapse within a year despite optimal primary treatment with complete tumor clearance at cytoreduction.

View Article and Find Full Text PDF

Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models.

Gynecol Oncol

August 2025

University of California San Diego, Rebecca and John Moores Cancer Center, Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, La Jolla, CA, USA. Electronic address:

Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve outcomes in metastatic, hormone receptor-positive breast cancer and low-grade serous ovarian carcinoma. Adult granulosa cell tumors (AGCTs) are similarly hormonally active tumors. We aimed to determine whether CDK4/6i were effective in pre-clinical models of AGCTs.

View Article and Find Full Text PDF

Hypotony after trabeculectomy (TLE) can lead to choroidal detachment (CD) and maculopathy. We present a case of retinal detachment caused by extensive retinal pigment epithelial (RPE) tears following hypotony following TLE surgery. A 67-year-old man underwent TLE in the left eye for open-angle glaucoma.

View Article and Find Full Text PDF

A 3-year-old boy presented with recurrent eczema that began at 2 months of age. The patient was treated by multiple dermatologists using topical steroids, topical immunosuppressants, and oral antihistamines. The patient was subsequently referred to our clinic for improved symptom control.

View Article and Find Full Text PDF

Metastatic ovarian cancer patients who have recurrent disease after multiple lines of prior treatment have dismal prognosis. The Kristen rat sarcoma viral oncogene homologue ( mutation is very rare in ovarian cancers and no approved KRAS G12C targeted treatment options exist for ovarian cancer. Here we present a case of metastatic ovarian serous adenocarcinoma in a female patient in her late 70s who was heavily pretreated with multiple lines of treatment before, showing an excellent durable response to KRAS G12C inhibitor sotorasib at reduced dose of 240 mg oral daily for over 26 months and ongoing.

View Article and Find Full Text PDF